I am very interested in basic studies of the correlates of immune protection as well as the immunologic correlates of vaccine-associated adverse events. Using measles as our primary model, we have examined immune responses generated following natural infection and vaccination in children of the developed and the developing world. Adverse events after vaccination are a growing concern and the lab has been involved and continues to be involved in studies of adverse events after vaccines for measles (increased mortality after the high titer formulation, autism and Crohns Disease after MMR), pertussis (local and systemic reactions), anthrax (all events), smallpox (death) and influenza (oculo-respiratory syndrome). We are also very interested in the interactions between virus (measles and HIV are our models) and retinoids both in vitro and in the field (Zimbabwe, Peru). We are developing proteosome-based vaccines (nasal delivery) for several respiratory viruses (measles, RSV, PIV3) as well as Toxoplasma gondii (Tg-AMA1) and Leishmania donovani (A2). Finally, we have an active Vaccine Evaluation Center that recruits subjects to ‘first-in-man’ Phase I and Phase II studies. In 2003, we studied a CpG-based hepatitis B vaccine, a pan-serotype, protein-based Streptocossus pneumoniae vaccine and a trivalent proteosome-based influenza vaccine.
The lab includes the National Center for Parasitology (NRCP), an external reference laboratory for health Canada that performs almost all diagnostic testing for parasitic diseases in the country. In the past several years he NRCP has developed novel assays or improved assays for a number of parasitic diseases (Chagas disease, leishmania, cyclosporiasis, strongyloidiasis). We have used standard and modified EIA techniques, PCR and SELDI-ToF MS. We are also actively involved in the development of novel treatments for parasitic diseases including imiquomod for leishmaniasis (Peru) and protease inhibitors for C parvum. (IFNg receptor KO mouse model) and c-MET antagonists for malaria (P berghei model).
Sampasa-Kanyinga H, Lévesque B, Anassour-Laouan-Sidi E, Côté S, Serhir B, Ward BJ, Libman MD, Drebot MA, Ndao M, Dewailly E.
Zoonotic Infections in Native Communities of James Bay, Canada. Vector Borne Zoonotic Dis. 2012 Jan 4. [Epub ahead of print]
Wagar LE, Rosella L, Crowcroft N, Lowcock B, Drohomyrecky PC, Foisy J, Gubbay J, Rebbapragada A, Winter AL, Achonu C, Ward BJ, Watts TH.
Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS One. 2011;6(11):e28063. Epub 2011 Nov 23.
Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, Sabaiduc S, Chan T, Petric M.
Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata. Pediatr Infect Dis J. 2011 Oct;30(10):833-9.
Soye KJ, Trottier C, Richardson CD, Ward BJ, Miller WH Jr.
RIG-I is required for the inhibition of measles virus by retinoids. PLoS One. 2011;6(7):e22323. Epub 2011 Jul 19.
Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, Halperin SA, Janjua NZ, Chan T, Sabaiduc S, Petric M. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011 Aug;128(2):e276-89. Epub 2011 Jul 18.
Campagna S, Lévesque B, Anassour-Laouan-Sidi E, Côté S, Serhir B, Ward BJ, Libman MD, Drebot MA, Makowski K, Andonova M, Ndao M, Dewailly E.
Seroprevalence of 10 zoonotic infections in 2 Canadian Cree communities. Diagn Microbiol Infect Dis. 2011 Jun;70(2):191-9. Epub 2011 Mar 12.
Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP.
Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010 Dec 22;5(12):e15559.
Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators.
Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis J. 2011 May;30(5):402-7.
Humphrey JH, Marinda E, Mutasa K, Moulton LH, Iliff PJ, Ntozini R, Chidawanyika H, Nathoo KJ, Tavengwa N, Jenkins A, Piwoz EG, Van de Perre P, Ward BJ; ZVITAMBO study group.
Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ. 2010 Dec 22;341:c6580. doi: 10.1136/bmj.c6580.
Ndao M, Rainczuk A, Rioux MC, Spithill TW, Ward BJ.
Is SELDI-TOF a valid tool for diagnostic biomarkers? Trends Parasitol. 2010 Dec;26(12):561-7. Epub 2010 Aug 12.